Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander H Stegh

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Expert Opinion on Therapeutic Targets|January 14, 2012
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perilsAlexander H Stegh
Integrative Biology : Quantitative Biosciences From Nano to Macro|August 4, 2012
Toward personalized cancer nanomedicine - past, present, and futureAlexander H Stegh
Oncotarget|January 9, 2014
Spherical nucleic acids for precision medicineChad A Mirkin, Alexander H Stegh
Cell Cycle (Georgetown, Tex.)|January 5, 2011
Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastomaAlexander H Stegh, Ronald A DePinho
Cancers|April 12, 2022
Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to BedsideAkanksha S Mahajan, Alexander H Stegh
Cell Cycle (Georgetown, Tex.)|October 28, 2015
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeuticsFotini M Kouri, Carissa Ritner, Alexander H Stegh
Antioxidants & Redox Signaling|May 3, 2023
Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of GlioblastomaKevin M Murnan, Craig Horbinski, Alexander H Stegh
Thescientificworldjournal|March 21, 2012
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyondFotini M Kouri, Samuel A Jensen, Alexander H Stegh
Methods in Molecular Biology (Clifton, N.J.)|May 18, 2019
Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in GlioblastomaSerena Tommasini-Ghelfi, Andrew Lee, Chad A Mirkin, et al.
Cell Cycle (Georgetown, Tex.)|September 5, 2008
What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulatorAlexander H Stegh, Lynda Chin, David N Louis, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Expert Opinion on Therapeutic Targets|January 14, 2012
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perilsAlexander H Stegh
Integrative Biology : Quantitative Biosciences From Nano to Macro|August 4, 2012
Toward personalized cancer nanomedicine - past, present, and futureAlexander H Stegh
Oncotarget|January 9, 2014
Spherical nucleic acids for precision medicineChad A Mirkin, Alexander H Stegh
Cell Cycle (Georgetown, Tex.)|January 5, 2011
Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastomaAlexander H Stegh, Ronald A DePinho
Cancers|April 12, 2022
Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to BedsideAkanksha S Mahajan, Alexander H Stegh
Cell Cycle (Georgetown, Tex.)|October 28, 2015
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeuticsFotini M Kouri, Carissa Ritner, Alexander H Stegh
Antioxidants & Redox Signaling|May 3, 2023
Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of GlioblastomaKevin M Murnan, Craig Horbinski, Alexander H Stegh
Thescientificworldjournal|March 21, 2012
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyondFotini M Kouri, Samuel A Jensen, Alexander H Stegh
Methods in Molecular Biology (Clifton, N.J.)|May 18, 2019
Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in GlioblastomaSerena Tommasini-Ghelfi, Andrew Lee, Chad A Mirkin, et al.
Cell Cycle (Georgetown, Tex.)|September 5, 2008
What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulatorAlexander H Stegh, Lynda Chin, David N Louis, et al.
Pageof 5